Showing results (221-230 of 233) with videos related to

Sort By:
Pageof 24
The Oncologist|March 19, 2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selectionLetizia Procaccio, Guido Giordano, Federico Nichetti, et al.
Cancers|April 3, 2021
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort StudySerena Di Cosimo, Barbara Tagliaferri, Daniele Generali, et al.
The Oncologist|August 14, 2014
Real-world study of everolimus in advanced progressive neuroendocrine tumorsFrancesco Panzuto, Maria Rinzivillo, Nicola Fazio, et al.
Cancers|July 2, 2021
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY StudyAlessandra Raimondi, Federica Palermo, Michele Prisciandaro, et al.
Annals of Surgical Oncology|April 11, 2024
Differences in Lymph Node Metastases Patterns Among Non-pancreatic Periampullary Cancers and Histologic Subtypes: An International Multicenter Retrospective Cohort Study and Systematic ReviewBas A Uijterwijk, Daniël H Lemmers, Giuseppe Kito Fusai, et al.
The Lancet. Oncology|March 14, 2020
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini, et al.
BMC Cancer|March 30, 2019
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Monica Niger, Federica Morano, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2025
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM studyDavide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, et al.
The Oncologist|January 5, 2019
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisClaudio Vernieri, Fabio Galli, Laura Ferrari, et al.
British Journal of Cancer|May 28, 2024
The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort studyBas A Uijterwijk, Daniël H Lemmers, Michele Ghidini, et al.
Pageof 24